Navigation Links
Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Date:11/26/2008

MIAMI, Nov. 26 /PRNewswire/ -- Thomas K. Equels, President and Managing Director of the Equels Law Firm, has been elected to the board of directors for Hemispherx BioPharma, Inc. (Amex: HEB), a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based disorders.

Equels' legal practice is devoted to litigation, with particular emphasis on civil racketeering, business torts and commercial matters. Prior to his board election, Equels served as Hemispherx BioPharma's litigation counsel.

For more than 25 years, Equels has represented national and state governments, and companies in the banking, insurance, aviation, pharmaceutical, construction and development industries. He has extensive experience in complex litigation matters including:

    -- Obtained a $26.8 million judgment in 2008 in a breach of contract
       action against Bear Stearns, for the Delaware Insurance Commissioner,
       related to an insolvent insurance company.
    -- Obtained a $15 million judgment in 2005 against boy band guru Lou
       Pearlman of Trans Continental Records, Inc.
    -- Obtained a $44 million judgment against Manuel Noriega for public money
       he misappropriated from the Republic of Panama.
    -- Recovered more than $100 million misappropriated and money laundered
       overseas by former insiders of a now defunct insurance company being
       liquidated by the State of Delaware's Insurance Commissioner.
    -- Obtained and collected a $10.6 million judgment against the FDIC for
       breach of contract involving a client's purchase of a national mortgage
       company owned by a failed savings and loan.
    -- Prosecuted a bank fraud claim against an international lender, which
       resulted in a jury awarding $2.6 million damages for fraud and an order
       invalidating a $9 million mortgage.

Equels earned a law degree with high honors from the Florida State University School of Law and earned a bachelor of arts degree, summa cum laude, from Troy State University. He is a member of The Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers.

About the Equels Law Firm

The Equels Law Firm has established itself as one of Florida's most effective and experienced law firms in the areas of complex litigation, government, business torts and personal injury law. The Equels Law Firm attorneys in Miami, Orlando and Tallahassee are known for providing high-quality, timely, efficient and personalized service to its local, national and international clients, whether representing them in either federal and state court or before federal, state or local governments. You can learn more about the Equels Law Firm at www.equelslaw.com or by calling Thomas Equels at (305) 859-7700.

About Hemispherx BioPharma

Hemispherx BioPharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(R) and Oragens. Ampligen(R) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.


'/>"/>
SOURCE Equels Law Firm
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
3. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
5. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
6. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):